RxDoctor Payments Data

Caitlin McMahon

Nurse Practitioner · Woodbury, NJNPI 1679100028

Payments from drug & device makers

$685in general payments, 2019–2025

Across 26 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$333
  • GSK$76
  • Verona Pharma, Inc.$73
  • Regeneron Healthcare Solutions, Inc.$72
  • United Therapeutics Corporation$35
  • Electromed, Inc.$21
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$685 in reported general payments places this provider in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$3,484
Medicare patients
37
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$41,990
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$13,359
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$8,863
Breo ElliptaFluticasone/Vilanterol19$7,937
Incruse ElliptaUmeclidinium Bromide14$5,364
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$4,801
Albuterol Sulfate HfaAlbuterol Sulfate52$2,036
Fluticasone Propionate36$498
Azelastine Hcl16$407
Prednisone149$342
Montelukast Sodium36$329
Azithromycin25$144
Doxycycline Hyclate27$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$76$64,15590 claims
AstraZenecaBreztri Aerosphere$333$13,35917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Woodbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →